Demographic and Clinical Characteristics of Mild, Young and Early COPD: A Cross-Sectional Analysis of 5468 Patients

J Clin Med. 2024 Dec 4;13(23):7380. doi: 10.3390/jcm13237380.

Abstract

Early, mild and young COPD concepts are not clearly defined and are often used interchangeably to refer to the onset of the disease. Objective: To describe and compare the characteristics of mild, young and early COPD in a large sample of COPD from primary and secondary care. Methods: Pooled analysis of individual data from four multicenter observational studies of patients with stable COPD (≥40 years, FEV1/FVC < 0.7, smoking ≥ 10 pack-years). Mild COPD was defined as FEV1% ≥ 65%; young COPD as <55 years; and early COPD as <55 years and smoking ≤ 20 pack-years. The relationship between FEV1(%), age and pack-years was analyzed with linear regression equations. Results: We included 5468 patients. Their mean age was 67 (SD: 9.6) years, and 85% were male. A total of 1158 (21.2%) patients had mild COPD; 636 (11.6%) had young COPD and 191 (3.5%) early COPD. The three groups shared common characteristics: they were more frequently female, younger and with less tobacco exposure compared with the remaining patients. Early COPD had fewer comorbidities and fewer COPD admissions, but no significant differences were found in ambulatory exacerbations. In linear regression analysis, the decline in FEV1(%) was more pronounced for the first 20 pack-years for all age groups and was even more important in younger patients. Conclusions: Mild, young and early COPD patients were more frequently women. The steepest decline in FEV1(%) was observed in individuals <55 years and smoking between 10 and 20 pack-years (early COPD), which highlights the importance of an early detection and implementation of preventive and therapeutic measures.

Keywords: COPD; early; mild; prognosis; young.

Grants and funding

The FyCEPOC and INSEPOC studies were funded by Laboratorios Esteve S.A (Barcelona, Spain). The NEREA study was funded by an unrestricted grant from J. Uriach y Compañía S.A (Barcelona, Spain). The DEPREPOC study was funded by Grupo Ferrer (Barcelona, Spain). No funding was received for the analysis, writing or submission of the current manuscript. The funding bodies had no involvement in the analysis and interpretation of data, the writing of the report or in the decision to submit the article for publication.